6p breast cancer pill denied daiy mail

You're referring to the recent news about the breast cancer pill, Olaparib, being denied approval by the UK's National Institute for Health and Care Excellence (NICE) for use on the National Health Service (NHS).

Here's a summary of the story:

• Olaparib is a targeted therapy that has been shown to be effective in treating certain types of breast cancer, particularly those with BRCA1 or BRCA2 mutations.
• The drug was approved by the European Medicines Agency (EMA) in 2017 for use in the EU, and has been available in the UK since then.
• However, NICE has now denied approval for Olaparib to be used on the NHS, citing concerns about its cost-effectiveness.
• The decision was based on a cost-benefit analysis, which found that the drug would not provide value for money for the NHS.
• The manufacturer of Olaparib, AstraZeneca, has expressed disappointment with the decision and is considering appealing the decision.

It's worth noting that this decision only applies to the NHS in England and Wales, and patients in Scotland and Northern Ireland may still be able to access the drug through their respective health services.

The denial of approval for Olaparib has sparked controversy, with many arguing that the drug could be a game-changer for breast cancer patients, particularly those with BRCA1 or BRCA2 mutations. Others have raised concerns about the cost of the drug and the need for more effective and affordable treatments.

The debate highlights the complex issues surrounding the approval and funding of new cancer treatments, and the need for a balanced approach that takes into account both the clinical benefits and the cost of these treatments.